Phytoestrogen Structure and Estrogenic Effects

Introduction to Phytoestrogens

Phytoestrogens are structurally similar to endogenous estrogens, particularly 17β-estradiol, which enables them to bind to estrogen receptors and exert estrogenic or antiestrogenic effects 1, 2
The American Heart Association notes that isoflavones have weak estrogenic effects in both animals and humans, working in a similar but less potent manner than endogenous estrogens 1, 2

Phytoestrogens, specifically isoflavonoids, have structural features that allow them to compete with endogenous estrogen for the ligand-binding domain of estrogen receptors 1, 2

Phytoestrogens can reduce the activity of enzymes that inactivate endogenous estrogens, potentially leading to increased active estrogen concentrations 3, 4, 5

The American Heart Association reports that phytoestrogens can stimulate epithelial cell proliferation in breasts of premenopausal women, a potential precursor of cancer 3, 4, 5
Despite structural similarity, phytoestrogens are significantly weaker than endogenous estrogens, requiring much higher concentrations to produce comparable effects 1, 2

Exogenous estradiol can promote estrogen-dependent breast cancer recurrence, highlighting the importance of these proliferative pathways in cancer management, as reported by the American Cancer Society 6

Some phytoestrogens may have differential effects depending on which estrogen receptor subtype they preferentially bind (ERα vs ERβ), with ERβ binding potentially leading to decreased cell proliferation, according to the American Society of Clinical Oncology 7

Phytoestrogens failed to show improvements in lipoprotein levels or endothelial function after 8 weeks of isoflavone treatment (80 mg/d) in healthy postmenopausal women 8
The American Heart Association states that clinical endpoint data from well-conducted trials are not available to make recommendations concerning use of soy for prevention of cardiovascular disease 8

None of the estrogens (including phytoestrogens) have been evaluated in humans for treatment of stroke 9

The American Cancer Society recommends that breast cancer patients should only consume moderate amounts of soy food as part of a healthy plant-based diet 10
The American Cancer Society warns that high doses of soy may increase the risk of estrogen-responsive cancers, such as breast or endometrial cancer, in certain individuals 10
Breast cancer patients should not intentionally consume high amounts of soy products or concentrated sources of soy, such as pills, powders, or supplements containing isolated or concentrated isoflavones 10

A study of 1,326 cases and 1,657 controls of African-American, Latina, and White women in the US found that phytoestrogen intake was not associated with breast cancer risk, with an odds ratio of 1.0 (95% CI: 0.80-1.3) for the highest vs lowest quartile 10
A study of 240 breast cancer cases in South Asian women in the UK found moderate evidence of a protective effect of phytoestrogen intake, with a 50% lower risk of breast cancer in the highest quartile of isoflavone intake (OR 0.58, 95% CI 0.33-1.00) 10

Women with ER-positive tumors should not increase their phytoestrogen intake, as genistein may stimulate the growth of ER-positive breast cancer cells and interfere with the anti-tumor activity of tamoxifen 10
Women with ER-negative tumors may safely consume moderate amounts of soy and other phytoestrogens, but the optimal amount and source are unclear 10